The firm has settled on a set of metabolite biomarkers, along with an algorithm, for its first version of a test for arterial plaque buildup.
The firm will adapt multiplex panels for prognosis of septic shock patients to its array-based portable diagnostic platform.
The new platform, called Fusion, is an addition to the Panther system and will run qPCR assays with three "mini panels" currently in the works.
The companies will use their respective technologies to develop multiplex molecular diagnostic panels for laboratory testing.
The firm priced each share at $.47, and plans to use the funding for general corporate purposes and working capital.
The scientists believe they have created a more accurate way to detect mutations that often lead to hereditary colorectal cancer.
The San Diego diagnostics firm's technology is designed for rapid, multiplexed, blood-based testing in a physician's office setting.
The special conditions of MDx use in the pediatric market may also present advantages in patient satisfaction metrics, a BioFire representative said.
The researchers are also developing the method in tandem with a more extensive pathogen profiling diagnostic platform from Swedish startup Q-linea.
NEW YORK (GenomeWeb News) – MRC Technology today announced a collaboration with Renishaw Diagnostics to identify and develop clinical diagnostic tests for infectious diseases.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.